.png){kind=icon}
返回
Defining clinical outcome pathways
.png){kind=icon}
OA
AI
DOI：10.1016/j.drudis.2022.02.008.png)
.png){kind=icon}
.png){kind=icon}
分享.png){kind=icon}
收藏
摘要
En 中文
Here, we propose a broad concept of 'Clinical Outcome Pathways' (COPs), which are defined as a series of key molecular and cellular events that underlie therapeutic effects of drug molecules. We formalize COPs as a chain of the following events: molecular initiating event (MIE) intermediate event(s) clinical outcome. We illustrate the concept with COP examples both for primary and alternative (i.e., drug repurposing) therapeutic applications. We also describe the elucidation of COPs for several drugs of interest using the publicly accessible Reasoning Over Biomedical Objects linked in Knowledge Oriented Pathways (ROBOKOP) biomedical knowledge graph-mining tool. We propose that broader use of COP uncovered with the help of biomedical knowledge graph mining will likely accelerate drug discovery and repurposing efforts.
Keyword:
Clinical outcome pathways
Key molecular events
Drug repurposing
Knowledge graphs
AI总结
对已上传原文的论文进行重点信息的提取，主要内容包括：简要概述、研究摘要、背景介绍、关键亮点、图文解析、展望与总结。
期刊
IF:
7.5
论文数:
6.4K
被引数:
2.3W
机构
引用论文
.png){kind=icon}
Applying Adverse Outcome Pathways (AOPs) to support Integrated Approaches to Testing and Assessment (IATA)应用不良结果途径 (aop) 以支持测试和评估的综合方法 (IATA)OAAI
OAAI分享收藏Chemotext: A Publicly Available Web Server for Mining Drug-Target-Disease Relationships in PubMedOAAI
OAAI分享收藏
查看更多内容